“`html
Tempus AI (TEM) experienced a 7.3% surge in stock price following FDA 510(k) clearance for its ECG-Low EF software on October 17, 2023. This marks the company’s second AI tool approved in cardiology, contributing to a 75% increase in revenues and nearly doubling gross profit in Q1 2025. In a significant partnership, Tempus AI entered a $200 million deal with AstraZeneca (AZN) and Pathos to enhance cancer diagnostics and drug discovery, raising its total contract value to over $1 billion.
In the last three months, TEM shares have risen 48.3%, significantly outperforming the Medical Info Systems industry (11.9% increase) and the Medical sector (1%). The FDA approval further allows clinicians to detect patients at risk for heart failure through standard ECGs, solidifying Tempus AI’s position in the diagnostics field with expanding revenues from its hereditary testing segment, which generated $63.5 million, reflecting a 23% increase in testing volumes.
Analysts project a 19.3% upside for TEM, suggesting a target price increase from the last closing price of $66.70. Despite the stock’s strong performance and promising fundamentals, its current valuation, at a forward price-to-sales ratio of 7.34, exceeds the industry average of 5.56, indicating a cautious outlook for short-term investors.
“`
